Prospectus for Issuance of Convertible Corporate Bonds to Undefined Targets (Revised Draft)

Guangdong Taiankang Pharmaceutical Co., Ltd.

Prospectus for Issuance of Convertible Corporate Bonds to Undefined Targets (Revised Draft)

Statement of the Issuer

I. The Company and the entire Board of Directors guarantee that the information disclosed in this announcement is true, accurate, and complete, and that there are no false or misleading statements or material omissions. They shall bear individual and joint legal responsibility for the truthfulness, accuracy, and completeness of the contents of this prospectus.

II. After the completion of this issuance of convertible corporate bonds to undefined targets, the Company shall be responsible for changes in its operations and earnings. Investors shall be responsible for the investment risks arising from this issuance of convertible corporate bonds to undefined targets.

III. This prospectus is a statement by the Company's Board of Directors regarding the issuance of convertible corporate bonds to undefined targets. Any contrary statement shall be a false statement.

IV. Investors with any questions should consult their own brokers, lawyers, professional accountants, or other professional advisors.

V. The matters described in this prospectus do not represent the substantive judgment, confirmation, approval, or approval of the matters related to the issuance of convertible corporate bonds to undefined targets by the approval authorities. The effectiveness and completion of the matters related to the issuance of convertible corporate bonds to undefined targets described in this prospectus are subject to the review and approval of the Shenzhen Stock Exchange for issuance and listing, and registration with the China Securities Regulatory Commission. The final plan will be subject to the registration by the China Securities Regulatory Commission.

VI. Any content in this prospectus involving investment benefits or performance forecasts does not constitute a commitment by the Company to any investor or related party. Investors and related parties should understand the difference between plans, forecasts, or commitments and be aware of investment risks.

1

Special Instructions

The terms used in this section have the same meaning as those defined in the "Definitions" section of this prospectus.

I. The method of issuing securities this time is: Issuance of convertible corporate bonds to undefined targets.

II. The relevant matters of this issuance have been reviewed and approved by the 17th and 18th meetings of the 5th Board of Directors and the 2025 Annual Shareholders' Meeting. This issuance is subject to review and approval by the Shenzhen Stock Exchange and registration with the China Securities Regulatory Commission before it can be implemented.

III. The total amount of capital to be raised from the issuance of convertible corporate bonds to undefined targets shall not exceed RMB 80,100.00 million (inclusive). After deducting issuance expenses, the net proceeds are intended to be invested in the following projects:

Note: The proposed investment of net proceeds for each fundraising project does not include the amount invested in projects prior to the Board of Directors' resolution on this issuance.